Within the same week, federal courts in several different states issued a series of rulings related to FDA oversight of the abortion drug mifepristone, but pointing in two different legal directions: in Virginia and Hawaii, judges argued that the FDA itself had not provided sufficient grounds for the agency's own restrictions, while in North Carolina, another judge blocked state-specific regulations because he found they conflicted with FDA authority. Yet paradoxically, after all those rulings, the most controversial regulations remain untouched. That is the crux of the story: courts can declare a policy illegal, but they don't necessarily have the power to remove it immediately — the ultimate authority still rests with the federal agency that issued it.
According to Louisiana Illuminator, federal judge Robert Ballou in Virginia ruled that the FDA had not provided sufficient grounds to justify restrictions imposed in 2023 on mifepristone — the most commonly used of two drugs that end pregnancy before 10 weeks. Around the same time, another judge in Hawaii issued a similar ruling in October of last year, arguing that these restrictions were arbitrary.
Abortion access advocates may be winning in the courtroom but face the risk of losing at the desk of a federal agency.
One regulation, two interpretations of safety
What makes the case complicated is that the 2023 restrictions themselves both tightened and loosened rules. According to The Independent, Judge Ballou in Charlottesville declared illegal the requirement that doctors and pharmacists must have special certification before prescribing and dispensing mifepristone — a regulation imposed by the Biden administration. Yet that same 2023 regulation for the first time allowed the drug to be sent by mail without an in-person examination, a relaxation that many doctors supporting abortion rights had welcomed.
In other words, Ballou's ruling was not a pure victory for the side advocating access to abortion medication — it attacks the very REMS mechanism (Risk Evaluation and Mitigation Strategy) that the FDA uses to both allow a drug on the market and control who receives it. According to Talking Points Memo, only 73 out of more than 20,000 drugs approved by the FDA are subject to the REMS mechanism, and Ballou cited data showing that the mortality rate associated with medication abortion is only 0.65 cases per 100,000 procedures — a figure he used to argue that such strict oversight is disproportionate to the actual risk.
Crucially: Ballou cannot unilaterally strike down the regulation. He can only force the FDA to reconsider — a legal procedure called a remand. The Independent notes that current federal law does not allow a judge to unilaterally invalidate a regulation, though he could do so later when handling a separate group of complaints related to the constitutional rights of providers.
A patchwork legal map: each state its own law
While Virginia and Hawaii push toward loosening restrictions, another front is unfolding in the opposite direction — not at the federal level but at the state level, where state governments set their own laws regardless of what the FDA says.
In North Carolina, according to WRAL, a federal judge just permanently blocked several restrictions imposed by the state on how abortion medication is dispensed, after Dr. Amy Bryant from the University of North Carolina (UNC) filed suit. The blocked regulations included a ban on non-physician medical staff dispensing the drug, a requirement for in-person dispensing, and mandatory in-person follow-up after taking the medication — all found by the court to conflict with FDA authority. Yet in that very same ruling, two other North Carolina regulations remained in place: a requirement for in-person counseling within 72 hours and mandatory ultrasound before prescribing. This exemplifies how courts are handling piece by piece of a larger puzzle, rather than issuing a sweeping ruling applied uniformly nationwide.
Moving in the complete opposite direction, Iowa is tightening on paper. According to thegazette.com, the state implemented new regulations starting July 1 restricting mail delivery of medication and remote prescribing, requiring patients to have an in-person exam before receiving an abortion pill — plus a law banning abortion after detection of fetal cardiac activity starting in 2024, which typically falls around the sixth week of pregnancy. However, according to law professor Sally Frank at Drake University, the new law is unlikely to significantly change actual access, since most Iowa women already sought remote medical care from doctors in shield law states beforehand, as they typically discover pregnancy only after the sixth week.
Louisiana: where doctors are prosecuted for a name on a prescription
A noteworthy detail raised by thegazette.com is that Louisiana has sought to prosecute a doctor simply because his name appeared on an abortion pill prescription sent to a patient in the state. This explains why some states are moving toward removing doctor names from prescriptions to protect them from criminal liability — an arms race between laws protecting remote-prescribing physicians and state laws criminalizing abortion.
Three opposing lawsuits ahead
What makes the entire picture even more uncertain are three separate lawsuits filed by attorneys general from states with abortion bans, according to Louisiana Illuminator, seeking to have courts restore restrictions to pre-2016 levels or even completely revoke mifepristone's marketing approval. The Missouri case, joined by Idaho and Kansas, seeks to return regulations to before the FDA loosened them. The Texas case, joined by Florida, goes further — seeking to completely nullify drug approval. According to Talking Points Memo, a panel of the Fifth Circuit Court of Appeals once sided with Louisiana in a related dispute, but the U.S. Supreme Court blocked that ruling while litigation continues.
The clash between two lines of precedent — one with federal judges in Virginia and Hawaii arguing the FDA is overreaching, the other with conservative state attorneys general arguing the FDA is going too far — creates a rare situation: the same set of regulations attacked from two opposite directions, with neither side achieving a decisive victory.
The FDA is where the real decisions happen, not in the courtroom
The crucial point many news reports overlook is: even as federal judges continuously issue rulings against the FDA, the agency is nearly immune to that pressure in the short term, because Louisiana Illuminator reported that the FDA is currently [conducting a safety review